Xhale is transforming healthcare through the application of exhaled breath in pharmaceuticals, health monitoring and diagnostics.
-
Corporate Overview
Xhale's team is dedicated to creating a world where breath-detectable SMART™ drugs are routinely used to increase drug safety and efficacy, and where Xhale's breath-based technologies are the standard of care in every applicable diagnostic and monitoring market. -
Clinical Trials Monitoring
Xhale's clinical trials monitoring system - a line of breath-based Medication Adherence monitors and SMART™ versions of trial drugs - provides the first method of proving that clinical trial participants took the right medication and the right dose at the right time during a clinical trial. -
SMART™ Drugs
Xhale's Self-Monitoring And Reporting Therapeutics (SMART™) enables any therapeutic drug to be made breath-detectable, with unique markers which are released upon ingestion and measured in the breath with a small Xhale monitor. -
Anesthesia Monitoring
Xhale's breath-based Propofol Monitor will be the first to allow monitoring of ongoing blood levels of propofol, the most commonly used IV-based anesthetic agent, providing anesthesiologists with a monitoring system for Propofol similar to that provided for gas anesthetic agents. -
Breath Diagnostics
Xhale's diagnostics pipeline includes breath-based Therapeutic Drug Monitoring, and devices to replace current blood and urine tests with real-time, point-of-care/point-of-need breath-based devices. These non-invasive breath-based diagnostics will be fast, easy to use, pain-free, safe and accurate.
